A probable interaction between warfarin and the antiretroviral TRIO study regimen

Michelle D. Liedtke, Amulya Vanguri, R. Chris Rath

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: To report a probable drug interaction between the antiretroviral TRIO regimen (ritonavir-boosted darunavir, etravirine, and raltegravir) and warfarin in an HIV-infected patient. CASE SUMMARY: In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen. Treatment had been maintained with warfarin for the past 5 years and emtricitabine monotherapy for the preceding 22 months. Emtricitabine was discontinued when the TRIO regimen was started. The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1). Following the initiation of the TRIO regimen, the mean weekly warfarin dose was increased to 19.3 mg (95% CI 18.5 to 20.1) and was maintained over the ensuing 71 weeks with a mean INR of 2.6 (95% CI 2.2 to 3.0). DISCUSSION: Information on the effect of newer antiretrovirals on warfarin metabolism, as well as the collective contribution of combination antiretroviral therapy including multiple agents that may alter warfarin metabolism, is limited. We predicted that warfarin dose requirements would change upon initiation of the TRIO regimen. Given the variability in INR that can occur with chronic warfarin treatment, weekly warfarin doses were averaged during emtricitabine monotherapy (90 weeks) and TRIO regimen (71 weeks) periods. Mean weekly warfarin doses increased by 45% (p < 0.001) following initiation of the TRIO regimen. Mean INR results for the 2 time periods were not significantly different, demonstrating that stable anticoagulation was maintained. The Horn drug interaction probability scale score to assess causation indicated a probable interaction. CONCLUSIONS: An increased weekly warfarin dose requirement is predicted when warfarin is used concurrently with the antiretroviral TRIO regimen. Increased INR monitoring is prudent when the combination is administered.

Original languageEnglish
Pages (from-to)e34-e34
JournalAnnals of Pharmacotherapy
Volume46
Issue number11
DOIs
StatePublished - 1 Nov 2012

Fingerprint

Warfarin
International Normalized Ratio
etravirine
Drug Interactions
Transgender Persons
Ritonavir
Therapeutics
Horns
Venous Thrombosis
Causality
HIV Infections
HIV

Keywords

  • Antiretroviral
  • Darunavir
  • Drug interaction
  • Etravirine
  • HIV
  • Integrase strand transfer inhibitor
  • Nonnucleoside reverse transcriptase inhibitor
  • Protease inhibitor
  • Raltegravir
  • Warfarin

Cite this

Liedtke, Michelle D. ; Vanguri, Amulya ; Chris Rath, R. / A probable interaction between warfarin and the antiretroviral TRIO study regimen. In: Annals of Pharmacotherapy. 2012 ; Vol. 46, No. 11. pp. e34-e34.
@article{c3b3343b61b946439bfefea4ebc3ce6f,
title = "A probable interaction between warfarin and the antiretroviral TRIO study regimen",
abstract = "OBJECTIVE: To report a probable drug interaction between the antiretroviral TRIO regimen (ritonavir-boosted darunavir, etravirine, and raltegravir) and warfarin in an HIV-infected patient. CASE SUMMARY: In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen. Treatment had been maintained with warfarin for the past 5 years and emtricitabine monotherapy for the preceding 22 months. Emtricitabine was discontinued when the TRIO regimen was started. The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95{\%} CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95{\%} CI 2.5 to 3.1). Following the initiation of the TRIO regimen, the mean weekly warfarin dose was increased to 19.3 mg (95{\%} CI 18.5 to 20.1) and was maintained over the ensuing 71 weeks with a mean INR of 2.6 (95{\%} CI 2.2 to 3.0). DISCUSSION: Information on the effect of newer antiretrovirals on warfarin metabolism, as well as the collective contribution of combination antiretroviral therapy including multiple agents that may alter warfarin metabolism, is limited. We predicted that warfarin dose requirements would change upon initiation of the TRIO regimen. Given the variability in INR that can occur with chronic warfarin treatment, weekly warfarin doses were averaged during emtricitabine monotherapy (90 weeks) and TRIO regimen (71 weeks) periods. Mean weekly warfarin doses increased by 45{\%} (p < 0.001) following initiation of the TRIO regimen. Mean INR results for the 2 time periods were not significantly different, demonstrating that stable anticoagulation was maintained. The Horn drug interaction probability scale score to assess causation indicated a probable interaction. CONCLUSIONS: An increased weekly warfarin dose requirement is predicted when warfarin is used concurrently with the antiretroviral TRIO regimen. Increased INR monitoring is prudent when the combination is administered.",
keywords = "Antiretroviral, Darunavir, Drug interaction, Etravirine, HIV, Integrase strand transfer inhibitor, Nonnucleoside reverse transcriptase inhibitor, Protease inhibitor, Raltegravir, Warfarin",
author = "Liedtke, {Michelle D.} and Amulya Vanguri and {Chris Rath}, R.",
year = "2012",
month = "11",
day = "1",
doi = "10.1345/aph.1R290",
language = "English",
volume = "46",
pages = "e34--e34",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "SAGE Publications Inc.",
number = "11",

}

A probable interaction between warfarin and the antiretroviral TRIO study regimen. / Liedtke, Michelle D.; Vanguri, Amulya; Chris Rath, R.

In: Annals of Pharmacotherapy, Vol. 46, No. 11, 01.11.2012, p. e34-e34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A probable interaction between warfarin and the antiretroviral TRIO study regimen

AU - Liedtke, Michelle D.

AU - Vanguri, Amulya

AU - Chris Rath, R.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - OBJECTIVE: To report a probable drug interaction between the antiretroviral TRIO regimen (ritonavir-boosted darunavir, etravirine, and raltegravir) and warfarin in an HIV-infected patient. CASE SUMMARY: In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen. Treatment had been maintained with warfarin for the past 5 years and emtricitabine monotherapy for the preceding 22 months. Emtricitabine was discontinued when the TRIO regimen was started. The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1). Following the initiation of the TRIO regimen, the mean weekly warfarin dose was increased to 19.3 mg (95% CI 18.5 to 20.1) and was maintained over the ensuing 71 weeks with a mean INR of 2.6 (95% CI 2.2 to 3.0). DISCUSSION: Information on the effect of newer antiretrovirals on warfarin metabolism, as well as the collective contribution of combination antiretroviral therapy including multiple agents that may alter warfarin metabolism, is limited. We predicted that warfarin dose requirements would change upon initiation of the TRIO regimen. Given the variability in INR that can occur with chronic warfarin treatment, weekly warfarin doses were averaged during emtricitabine monotherapy (90 weeks) and TRIO regimen (71 weeks) periods. Mean weekly warfarin doses increased by 45% (p < 0.001) following initiation of the TRIO regimen. Mean INR results for the 2 time periods were not significantly different, demonstrating that stable anticoagulation was maintained. The Horn drug interaction probability scale score to assess causation indicated a probable interaction. CONCLUSIONS: An increased weekly warfarin dose requirement is predicted when warfarin is used concurrently with the antiretroviral TRIO regimen. Increased INR monitoring is prudent when the combination is administered.

AB - OBJECTIVE: To report a probable drug interaction between the antiretroviral TRIO regimen (ritonavir-boosted darunavir, etravirine, and raltegravir) and warfarin in an HIV-infected patient. CASE SUMMARY: In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen. Treatment had been maintained with warfarin for the past 5 years and emtricitabine monotherapy for the preceding 22 months. Emtricitabine was discontinued when the TRIO regimen was started. The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1). Following the initiation of the TRIO regimen, the mean weekly warfarin dose was increased to 19.3 mg (95% CI 18.5 to 20.1) and was maintained over the ensuing 71 weeks with a mean INR of 2.6 (95% CI 2.2 to 3.0). DISCUSSION: Information on the effect of newer antiretrovirals on warfarin metabolism, as well as the collective contribution of combination antiretroviral therapy including multiple agents that may alter warfarin metabolism, is limited. We predicted that warfarin dose requirements would change upon initiation of the TRIO regimen. Given the variability in INR that can occur with chronic warfarin treatment, weekly warfarin doses were averaged during emtricitabine monotherapy (90 weeks) and TRIO regimen (71 weeks) periods. Mean weekly warfarin doses increased by 45% (p < 0.001) following initiation of the TRIO regimen. Mean INR results for the 2 time periods were not significantly different, demonstrating that stable anticoagulation was maintained. The Horn drug interaction probability scale score to assess causation indicated a probable interaction. CONCLUSIONS: An increased weekly warfarin dose requirement is predicted when warfarin is used concurrently with the antiretroviral TRIO regimen. Increased INR monitoring is prudent when the combination is administered.

KW - Antiretroviral

KW - Darunavir

KW - Drug interaction

KW - Etravirine

KW - HIV

KW - Integrase strand transfer inhibitor

KW - Nonnucleoside reverse transcriptase inhibitor

KW - Protease inhibitor

KW - Raltegravir

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84869222688&partnerID=8YFLogxK

U2 - 10.1345/aph.1R290

DO - 10.1345/aph.1R290

M3 - Article

C2 - 23115227

AN - SCOPUS:84869222688

VL - 46

SP - e34-e34

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 11

ER -